Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Puxitatug samrotecan by AstraZeneca for Metastatic Biliary Tract Cancer: Likelihood of Approval
Puxitatug samrotecan is under clinical development by AstraZeneca and currently in Phase II for Metastatic Biliary Tract Cancer. According to...
Puxitatug samrotecan by AstraZeneca for Metastatic Breast Cancer: Likelihood of Approval
Puxitatug samrotecan is under clinical development by AstraZeneca and currently in Phase II for Metastatic Breast Cancer. According to GlobalData,...
Puxitatug samrotecan by AstraZeneca for Solid Tumor: Likelihood of Approval
Puxitatug samrotecan is under clinical development by AstraZeneca and currently in Phase II for Solid Tumor. According to GlobalData, Phase...
Puxitatug samrotecan by AstraZeneca for Endometrial Cancer: Likelihood of Approval
Puxitatug samrotecan is under clinical development by AstraZeneca and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase...
Puxitatug samrotecan by AstraZeneca for Fallopian Tube Cancer: Likelihood of Approval
Puxitatug samrotecan is under clinical development by AstraZeneca and currently in Phase II for Fallopian Tube Cancer. According to GlobalData,...
Puxitatug samrotecan by AstraZeneca for Peritoneal Cancer: Likelihood of Approval
Puxitatug samrotecan is under clinical development by AstraZeneca and currently in Phase II for Peritoneal Cancer. According to GlobalData, Phase...
Puxitatug samrotecan by AstraZeneca for Metastatic Bile Duct Cancer: Likelihood of Approval
Puxitatug samrotecan is under clinical development by AstraZeneca and currently in Phase II for Metastatic Bile Duct Cancer. According to...